| 4.02 0 (0%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.33 | 1-year : | 6.02 |
| Resists | First : | 4.56 | Second : | 5.15 |
| Pivot price | 3.98  |
|||
| Supports | First : | 3.6 | Second : | 2.99 |
| MAs | MA(5) : | 3.95  |
MA(20) : | 4.04 |
| MA(100) : | 8.12 |
MA(250) : | 18.19 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 40.5 |
| RSI | RSI(14): 41.9 | |||
| 52-week | High : | 98.19 | Low : | 3.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCTX ] has closed below upper band by 44.8%. Bollinger Bands are 85.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.22 - 4.24 | 4.24 - 4.26 |
| Low: | 3.73 - 3.75 | 3.75 - 3.76 |
| Close: | 3.99 - 4.02 | 4.02 - 4.05 |
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Sat, 28 Feb 2026
BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Thu, 26 Feb 2026
BCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Thu, 26 Feb 2026
BriaCell Therapeutics (BCTX) files Form 25 to remove Warrants from Nasdaq - Stock Titan
Wed, 18 Feb 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - GlobeNewswire
Tue, 17 Feb 2026
BriaCell Receives Positive Recommendation from Data Safety - GlobeNewswire
Wed, 14 Jan 2026
What's Going On With BriaCell Therapeutics Stock Wednesday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 142 (K) |
| Shares Short P.Month | 281 (K) |
| EPS | -33.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -161.7 % |
| Return on Equity (ttm) | -444.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|